---
created: 2025-04-13
updated: 2025-04-13T10:53
id: OuX&`OD6S4
specialty: pulmo
specialty_id: 151
tags:
  - source/ak-original-decks::step-1::zanki-step-decks::zanki-respiratory::respiratory-pathology
  - "source/ak-step1-v11:": 
  - theme/firstaid::16-respiratory::04-pathology::24-lung-cancer
  - "source/ak-step1-v11:": 
  - theme/firstaid::16-respiratory::04-pathology::24-lung-cancer::non-small-cell-carcinoma::adenocarcinoma
  - "source/ak-step1-v11:": 
  - source/ome-banner::clinical::02-pulmonology::02-lung-cancer
  - "source/ak-step1-v11:": 
  - theme/pathoma::09-respiratory::08-lung-cancer
  - "source/ak-step1-v11:": 
  - theme/physeo::11-pathology::03-pulmonary-pathology::20-lung-cancer
  - "source/ak-step1-v11:": 
  - theme/pixorize::02-biochem::12-lung-cancer::03-adenocarcinoma
  - source/ak-step1-v11::^other::^expn::bgadd
  - source/ak-step1-v11::^other::^highyield::4-loweryield
  - source/ak-step1-v11::^systems::respiratory::bgadds"
type: flashcard
---

# Question
"Testing for ""**driver mutations::genetics**"" in adenocarcinoma of the lung guides systemic therapy in advanced disease"

---

# Answer
eg. EGFR+ tumors being treated with erlotinib or EML4-ALK+ tumors being treated with crizotinib